SHANGHAI, May 21, 2014 -- WuXi PharmaTech (NYSE: WX) today announced that its toxicology facility in Suzhou had received a statement of Good Laboratory Practice (GLP) from the Belgium Scientific Institute of Public Health on behalf of the Organization for Economic Cooperation and Development (OECD) after successfully passing three GLP inspections conducted by the Belgium GLP Monitorate. Good Laboratory Practice is a quality system concerned with the organizational processes and conditions under which health safety studies are planned, performed, monitored, recorded, archived, and reported.
The statement resulted from a five-day inspection conducted by a team of inspectors from the Belgian national GLP compliance monitoring authority in February 2014. The inspection included an audit of 22 studies in areas that included general toxicology, genetic toxicology, safety pharmacology, dermal irritation, skin phototoxicity, and immunology. The facility successfully passed two previous inspections by the OECD in 2010 and 2012, and also passed two inspections by the SFDA/CFDA.
"The Belgian GLP statement for our toxicology facility is a further acknowledgment of the quality of our services, which meet the highest international standards," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "With this recognition, WuXi has further solidified its leadership in offering the highest-quality toxicology service in China. Toxicology is an important part of WuXi's comprehensive, fully integrated platform of services for our global and domestic pharmaceutical and biotech clients."
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit http://www.wuxiapptec.com or contact:
Aaron Shi (for the media)
Ronald Aldridge (for investors)